SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

Bitfarms is trending as investors discuss its recent financing deal involving capped calls, which some believe will fuel expansion while others are skeptical about its use. Community members are debating the potential for dilution and its impact on the stock's future growth, with some drawing comparisons to other Bitcoin miners that have undertaken similar strategies. Bullish sentiment remains strong overall, fueled by the company's shift towards high-performance computing (HPC) and artificial intelligence (AI) infrastructure.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to a lawsuit from Singapore's GIC alleging inflated revenue figures, sparking debate about its impact. The community is divided, with some viewing it as a buying opportunity amidst recycled headlines and others expressing concern. Discussions also include delivery numbers, battery swap technology, and the broader context of Chinese EV competition.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxis Precision Medicines is trending due to positive topline results from Phase 3 trials of ulixacaltamide HCl for essential tremor, sparking significant pre-market gains and heavy trading volume. The community is focused on the high institutional ownership potentially leading to a short squeeze, with some speculating on price targets. This movement occurs within the context of the essential tremor treatment space, where there is a large unmet need for effective therapies.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending as analysts update their ratings, citing a clear path to growth and potential investor sentiment improvement, especially with the company's AI integrations. Community discussions revolve around potential revival of the AI software/enterprise trade and possible short-term trading opportunities. The stock also garnered attention following Salesforce and Google's deepened partnership with Gemini integration, further emphasizing the company's focus on AI.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is trending after reporting strong Q3 earnings, driven by surging AI chip demand, and raising its 2025 revenue growth outlook. Community members are discussing the company's impressive profit increase and potential for further gains, while also noting geopolitical risks. Some analysts are raising price targets, citing TSMC's key role in the AI boom and strong guidance.

Veritone, Inc. engages in the provision of artificial intelligence (AI) computing solutions to media and entertainment, government, and legal and compliance industries. It operates through the following segments: Advertising, aiWARE SaaS Solutions, and aiWARE Content Licensing and Media Services. The Advertising segment places advertisements for clients, primarily with radio broadcasters, podcasters and digital media producers. The aiWARE SaaS Solutions segment offers solutions through a combination of its direct sales force and indirect channel partners, such as value-added resellers (VARs), distributors, system integrators, managed services providers, and referral partners. The aiWARE Content Licensing and Media Services segment sells and markets activities relating to its digital content licensing services business through its direct sales force. The company was founded by Chad Edward Steelberg and Ryan S. Steelberg on June 13, 2014 and is headquartered in Denver, CO.

Veritone Inc

Veritone (VERI) is trending due to a registered direct offering of $75 million, leading to community discussion about dilution and management's timing. While some investors express concerns about the offering's impact on share value, others view it as a necessary step for growth and debt repayment, emphasizing the company's long-term potential in the AI sector. Community members are actively debating whether this dip presents a buying opportunity or signals further downside.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

ABAT is trending due to the termination of a DOE grant for its lithium hydroxide project, leading to a significant price drop and high trading volume. While the company is appealing the decision and states the project will continue unchanged, the community is debating the impact of the lost funding and potential need for alternative financing. Some investors view the dip as a buying opportunity, citing the company's long-term potential and strategic importance in the domestic battery technology sector.

Aurora Innovation, Inc. engages in the design and development of automobile hardware, software, and provision of data services. It offers the Aurora Driver which allows a vehicle to drive itself. The company was founded by Christopher Urmson, Sterling Anderson and James Andrew Bagnell in 2017 and is headquartered in Pittsburgh, PA.

Aurora Innovation Inc - Ordinary Shares - Class A

Aurora Innovation is trending as the community discusses the potential impact of new partnerships and upcoming earnings. Bullish sentiment is fueled by institutional buying, progress in autonomous trucking technology, and analysts setting high price targets. Discussions also revolve around the company's path to commercialization and its competitive positioning within the autonomous vehicle sector.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending as gold prices surge, driven by safe-haven demand amid geopolitical tensions and a weaker dollar. The Stocktwits community is actively debating whether this rally is sustainable, with some anticipating a pullback and others predicting further gains. Discussions include potential price targets and the impact of central bank policies on gold's value.

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

MVST is trending as investors discuss its valuation relative to peers and potential catalysts like earnings and expansion plans. Community members are pointing to potential short squeezes and institutional buying, while also debating the company's ties to China. Overall, the discussion revolves around whether the stock is undervalued and poised for further gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Sionna Therapeutics, Inc. (SION) Rating Upgrade to Buy

Sionna Therapeutics, Inc. (SION) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts See a 66.51% Upside in Sionna Therapeutics, Inc. (SION): Can the Stock Really Move This High?

The mean of analysts' price targets for Sionna Therapeutics, Inc. (SION) points to a 66.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The short squeeze in Sionna Therapeutics shares that followed a 45% post-earnings rally has cooled, with shorts rising to 23.7% of free float from 21.5% as the stock slipped about 10% last week.The biopharmaceutical firm, which is developing novel therapies for cystic fibrosis, drew conflicting sell-side views, according to The Fly, which compiled data on the short squeeze from Ortex.&nbsp;Raymond James initiated coverage with a ‘Strong Buy’ rating and $45 price target, saying Sionna has the best chance in the industry at breaking Vertex Pharmaceuticals’ stronghold in cystic fibrosis. RBC Capital Markets began at ‘Sector Perform’ with a $22 target, noting that existing treatments set a high bar and that Sionna’s next key data readouts in mid-2026 may not meaningfully de-risk the program.Sionna is advancing two first-in-class NBD1 stabilizers, SION-719 and SION-451. Both produced positive Phase 1 safety and pharmacokinetic results in June, exceeding target exposure levels.&nbsp;The company plans to start a Phase 2a proof-of-concept trial of SION-719 as an add-on to standard of care in the second half of 2025 and a Phase 1 trial of SION-451 in two proprietary dual combinations over the same period, with topline data from both expected in mid-2026.&nbsp;Preclinical findings presented in June showed that the stabilizers, when combined with complementary modulators, enabled full correction of F508del-CFTR in models.In second-quarter results released last month, Sionna reported a net loss of $18.1 million, or a loss of $0.41 per share, compared with a loss of $2.71 a year earlier, on higher R&amp;D expenses of $15.4 million.&nbsp;General and administrative expenses rose to $6.5 million from $3.1 million. The company ended June with $337.3 million in cash and equivalents, which it stated&nbsp;should be sufficient to fund operations&nbsp;through 2028.On Stocktwits, retail sentiment for Sionna was ‘bearish’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/SION">Sionna’s stock</a> has declined 4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sionna’s stock (SION) has declined 4% so far in 2025. (Photo credit: Getty Images)

Sionna Short Squeeze Fades As Raymond James Backs Cystic Fibrosis Breakthrough, RBC Warns Treatments Set High Bar

The biopharmaceutical firm’s shorts climbed to 23.7% of free float last week as the stock slipped 10%.

Equity

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a robust pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.

Sionna Therapeutics Inc.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$31.45
Prev Close	$30.91
Open	$30.80
Dividend Yield	N/A
50-Day Moving Average	$24.77
Beta	0.98
Avg. Volume	321,472.90
PE Ratio	N/A

52-Week High	$31.47
52-Week Low	$7.26
Market Capitalization	$1.36B
EPS (Annual)	-$1.40
Price to Book	4.05
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SION
Sionna Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SION News

SIONSionna Therapeutics Inc